世界最新医学信息文摘（连续型电子期刊）
世界最新醫學信息文摘（連續型電子期刊）
세계최신의학신식문적（련속형전자기간）
World Latest Medicine Information
2015年
42期
8-9
,共2页
雷贝拉唑%联合%莫沙必利%反流性食管炎%疗效分析
雷貝拉唑%聯閤%莫沙必利%反流性食管炎%療效分析
뢰패랍서%연합%막사필리%반류성식관염%료효분석
Rabeprazole%Union%Mosapride%Refiux esophagitis%Efficacy
目的：对反流性食管炎患者给予雷贝拉唑、莫沙必利联合治疗，观察临床效果。方法选取近两年收治的86例反流性食管炎患者，按照随机分组法将患者分为治疗组和对照组，每组43例，对照组患者给予法莫替丁片和莫沙必利治疗，治疗组患者给予雷贝拉唑联合莫沙必利治疗，观察对比两组患者的临床疗效及用药安全性。结果治疗组43例患者中显效35例，有效7例，无效1例，总有效率为97.7%，对照组43例患者中显效20例，有效13例，无效10例，总有效率为76.7%，两组比较差异具有显著性（P<0.05)。治疗后胃镜下食管炎愈合率治疗组明显高于对照组，两组比较差异具有显著性(P<0.05)。两组患者治疗过程中不良反应发生情况比较无显著性差异(P>0.05)。结论对于反流性食管炎给予雷贝拉唑联合莫沙必利治疗，能够显著提高治疗效果，不良反应少，安全性能高，在临床有推广使用价值。
目的：對反流性食管炎患者給予雷貝拉唑、莫沙必利聯閤治療，觀察臨床效果。方法選取近兩年收治的86例反流性食管炎患者，按照隨機分組法將患者分為治療組和對照組，每組43例，對照組患者給予法莫替丁片和莫沙必利治療，治療組患者給予雷貝拉唑聯閤莫沙必利治療，觀察對比兩組患者的臨床療效及用藥安全性。結果治療組43例患者中顯效35例，有效7例，無效1例，總有效率為97.7%，對照組43例患者中顯效20例，有效13例，無效10例，總有效率為76.7%，兩組比較差異具有顯著性（P<0.05)。治療後胃鏡下食管炎愈閤率治療組明顯高于對照組，兩組比較差異具有顯著性(P<0.05)。兩組患者治療過程中不良反應髮生情況比較無顯著性差異(P>0.05)。結論對于反流性食管炎給予雷貝拉唑聯閤莫沙必利治療，能夠顯著提高治療效果，不良反應少，安全性能高，在臨床有推廣使用價值。
목적：대반류성식관염환자급여뢰패랍서、막사필리연합치료，관찰림상효과。방법선취근량년수치적86례반류성식관염환자，안조수궤분조법장환자분위치료조화대조조，매조43례，대조조환자급여법막체정편화막사필리치료，치료조환자급여뢰패랍서연합막사필리치료，관찰대비량조환자적림상료효급용약안전성。결과치료조43례환자중현효35례，유효7례，무효1례，총유효솔위97.7%，대조조43례환자중현효20례，유효13례，무효10례，총유효솔위76.7%，량조비교차이구유현저성（P<0.05)。치료후위경하식관염유합솔치료조명현고우대조조，량조비교차이구유현저성(P<0.05)。량조환자치료과정중불량반응발생정황비교무현저성차이(P>0.05)。결론대우반류성식관염급여뢰패랍서연합막사필리치료，능구현저제고치료효과，불량반응소，안전성능고，재림상유추엄사용개치。
Objective: Patients with refiux esophagitis given rabeprazole, mosapride combination therapy, clinical effect.Methods:Past two years, 86 cases were treated with refiux esophagitis patients, according to randomized method were divided into treatment group and control group, 43 patients in the control group of patients in each group given famotidine and mosapride The treatment group were treated with rabeprazole mosapride treatment, clinical efficacy and safety of drugs compared two groups of patients.Results:The treatment group of 43 patients, 35 cases markedly effective in 7 cases, 1 case, the total effective rate was 97.7% in the control group of 43 patients, 20 cases markedly effective in 13 cases, 10 cases, total effective rate was 76.7% , the difference was significant (P <0.05). After treatment, endoscopic esophagitis healing rate of treatment group was significantly higher, the difference was significant (P <0.05). There was no significant difference (P> 0.05) in two groups of patients during treatment adverse events. Conclusion:Refiux esophagitis give rabeprazole mosapride treatment can significantly improve the therapeutic effect, less adverse reactions, high safety performance, promoting the use of clinical value.
